Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for OCGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -0.021M
March 31, 2026 -0.006M
December 31, 2025 -0.035M
September 30, 2025 -0.086M
June 30, 2025 -0.088M
March 31, 2025 -0.102M
December 31, 2024 -0.013M
September 30, 2024 -0.507M
June 30, 2024 -0.513M
March 31, 2024 -2.352M
December 31, 2023 -2.722M
September 30, 2023 -3.365M
June 30, 2023 5.723M
March 31, 2023 3.441M
December 31, 2022 -15.30M
September 30, 2022 -0.083M
June 30, 2022 -1.366M
March 31, 2022 -0.223M
December 31, 2021 -0.192M
September 30, 2021 -0.35M
June 30, 2021 -1.013M
March 31, 2021 -0.261M
December 31, 2020 -0.2513M
September 30, 2020 -0.021M
June 30, 2020 0.0182M
Date Value
March 31, 2020 -0.0527M
December 31, 2019 -0.0206M
September 30, 2019 -2.204M
June 30, 2019 -0.1215M
March 31, 2019 -0.0106M
December 31, 2018 0.00
September 30, 2018 1.757M
June 30, 2018 -1.479M
March 31, 2018 -0.355M
December 31, 2017 0.747M
September 30, 2017 6.104M
June 30, 2017 -0.038M
March 31, 2017 -8.043M
December 31, 2016 -0.003M
September 30, 2016 -0.003M
June 30, 2016 -0.282M
March 31, 2016 -0.032M
December 31, 2015 -0.131M
September 30, 2015 -0.498M
June 30, 2015 -0.405M
March 31, 2015 -0.915M
December 31, 2014 -1.744M
September 30, 2014 -1.384M
June 30, 2014 -0.073M
March 31, 2014 -0.12M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -8.529M
Biogen, Inc. -3.839B
Gilead Sciences, Inc. -10.35B
MannKind Corp. 17.91M
Vertex Pharmaceuticals, Inc. -45.80M